A Pharmacoeconomic Evaluation of the Myocardial Ischaemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study in the United Kingdom

Objective: To determine the short-term healthcare costs associated with intensive lipid lowering with atorvastatin initiated within 24–96 hours of the occurrence of acute coronary syndrome (ACS) in patients in the UK.